Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET

Company Participants

Louise Wilkie – Vice President-Investor Relations and Corporate Communications

Sandy Macrae – Chief Executive Officer

Nathalie Dubois-Stringfellow – Chief Development Officer

Mark McClung – Chief Operating Officer

Jason Fontenot – Chief Scientific Officer

Prathyusha Duraibabu – Chief Financial Officer

Lisa Rojkjaer – Chief Medical Officer

Conference Call Participants

Maury Raycroft – Jefferies

Luca Issi – RBC Capital

Greg Harrison – Bank of America

Gena Wang – Barclays

Anvita Gupta – Cowen

Nicole Germino – Truist

Patrick Trucchio – H.C. Wainwright

Operator

Good day, and thank you for standing by. Welcome to the Sangamo Second Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Louise Wilkie

Thank you. Good afternoon. I’m Louise Wilkie, Sangamo’s Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Lisa Rojkjaer, Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com under the Investors & Media section on the Events and Presentations page.

This call includes forward-looking statements regarding Sangamo’s current expectations. These statements include, but are not limited to, statements relating to the therapeutic and commercial potential of our product candidates, the anticipated plans and time lines of Sangamo and our collaborators for regulatory submissions, initiating and conducting clinical trials, screening, and dosing patients and presenting clinical data, advancements of our product candidates, anticipated feedback from and interactions with regulatory agencies, advancements of preclinical programs to the clinic, our strategic reprioritization and the anticipated benefits thereof. The sufficiency of our resources, cash runway, and plans to seek additional capital, our estimated financial guidance for 2023 and estimates of 2024 operating expenses, upcoming catalysts and milestones and other statements that are not historical facts.

Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC specifically on our annual report on Form 10-K for the fiscal year ended December 31, 2022 as supplemented by our quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in our press release, which is available on our website.